EpiCast Report: Migraine – Epidemiology Forecast to 2026

2017-08-10
Price :
Published : Aug-2017
No. of Pages : 30

EpiCast Report: Migraine – Epidemiology Forecast to 2026

Summary

Migraine is typically characterized by recurring headaches and throbbing pain on one side of the head accompanied by nausea, vomiting, or increased sensitivity to light or smell (Bigal and Lipton, 2006). While most migraineurs experience episodic migraines (EM), a small percentage suffers from chronic migraine (CM). Migraines are also classified into migraine with aura (MWA), in which the migraine is accompanied by other sensory symptoms, and migraine without aura (MOA).

In 2016, there were 73,914,635 total prevalent cases of migraine in adults ages 18 years and older in the 7MM. The US had the most cases, with 30,233,942, making up 40.90% of cases in the 7MM. Italy had the second most cases, with 12,231,868 cases, or 16.55% of cases in the 7MM. Spain had the fewest cases, with 2,199,892 cases (2.98% of cases in the 7MM). Italy also had the highest prevalence of migraine, with 23.63% of adult’s ages 18 years and older experiencing migraine in 2016. Spain had the lowest prevalence, at 5.54%.

In the 7MM, the number of total prevalent cases of migraine is expected to grow to 74,543,569 by 2026, at an Annual Growth Rate (AGR) of 0.09%. The US, France, Spain, and the UK are expected to see small increases in the number of total prevalent migraine cases, while Germany, Italy, and Japan are expected to see small decreases. The largest changes are expected in the US (AGR 0.60%) and Japan (AGR negative 0.87%). Since age- and sex-specific prevalence was held constant throughout the forecast period, all changes in the total prevalent cases of migraine are the result of demographic changes.

Our epidemiologists estimate that 1.61% of total migraine cases in the 7MM in 2016 were CM, corresponding to 1,189,614 cases. Due to the lack of country-specific sources, this percentage was applied to all markets.

The report “EpiCast Report: Migraine – Epidemiology Forecast to 2026″ provides an overview of the risk factors, comorbidities, and the global and historical trends for migraine in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases (diagnosed and undiagnosed) of migraine segmented by sex and age (for ages 18 years and older) in these markets. This forecast is further segmented by migraine frequency into EM and CM.

Scope

- The Migraine EpiCast Report provides an overview of the risk factors and global trends of migraine in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of migraine segmented by sex and age (for ages 18 years and older) in these markets. This forecast is further segmented by migraine frequency into episodic migraine (EM) and chronic migraine (CM).
- The migraine epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Migraine EpiCast report will allow you to –
- Develop business strategies by understanding the trends shaping and driving the global migraine market.
- Quantify patient populations in the global migraine market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for migraine therapeutics in each of the markets covered.
- Identify the percentage of migraine prevalent cases by frequency.

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : GlobalData
More Reports
Title Price Buy Now

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Venezuela

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Venezuela Summary Venezuela ranked 187 out of 190 countries in ease of doing business. In July 2017, rating firm Standard & Poor's downgraded Venezuela's economy to CCC with a negative outlook. Moody's also downgraded its rating to Caa3 with a negative outlook, while Fitch rated it at CCC with a negative outlook. Venezuela is one of the emerging pharmaceutical markets in South America, with a major dependence on imports. However, economic and political turmoil along with inefficient patent laws and drug pricing policies are major barriers. The value of the market was US$12.6 Billion in 2015, having increased from US$5.7 Billion in 2009, at a Compound Annual Growth Rate (CAGR) of 14.1%. Drug prices in Venezuela are ......
$1995

Hemorrhage Global Clinical Trials Review, H2, 2017

Hemorrhage Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hemorrhage Global Clinical Trials Review, H2, 2017" provides an overview of Hemorrhage clinical trials scenario. This report provides top line data relating to the clinical trials on Hemorrhage. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials ......
$2500

Hepatitis C Global Clinical Trials Review, H2, 2017

Hepatitis C Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hepatitis C Global Clinical Trials Review, H2, 2017" provides an overview of Hepatitis C clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatitis C. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical tri......
$2500

Herpes Zoster (Shingles) Global Clinical Trials Review, H2, 2017

Herpes Zoster (Shingles) Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Herpes Zoster (Shingles) Global Clinical Trials Review, H2, 2017" provides an overview of Herpes Zoster (Shingles) clinical trials scenario. This report provides top line data relating to the clinical trials on Herpes Zoster (Shingles). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - ......
$2500

Hemorrhagic Fever Global Clinical Trials Review, H2, 2017

Hemorrhagic Fever Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hemorrhagic Fever Global Clinical Trials Review, H2, 2017" provides an overview of Hemorrhagic Fever clinical trials scenario. This report provides top line data relating to the clinical trials on Hemorrhagic Fever. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trial......
$2500

Hepatitis D Global Clinical Trials Review, H2, 2017

Hepatitis D Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hepatitis D Global Clinical Trials Review, H2, 2017" provides an overview of Hepatitis D clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatitis D. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical tri......
$2500

Heterozygous familial hypercholesterolemia (heFH) Global Clinical Trials Review, H2, 2017

Heterozygous familial hypercholesterolemia (heFH) Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Heterozygous familial hypercholesterolemia (heFH) Global Clinical Trials Review, H2, 2017" provides an overview of Heterozygous familial hypercholesterolemia (heFH) clinical trials scenario. This report provides top line data relating to the clinical trials on Heterozygous familial hypercholesterolemia (heFH). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing......
$2500

Hemorrhagic Shock Global Clinical Trials Review, H2, 2017

Hemorrhagic Shock Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hemorrhagic Shock Global Clinical Trials Review, H2, 2017" provides an overview of Hemorrhagic Shock clinical trials scenario. This report provides top line data relating to the clinical trials on Hemorrhagic Shock. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trial......
$2500

Hepatitis E Global Clinical Trials Review, H2, 2017

Hepatitis E Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hepatitis E Global Clinical Trials Review, H2, 2017" provides an overview of Hepatitis E clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatitis E. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical tri......
$2500

Hemorrhoids Global Clinical Trials Review, H2, 2017

Hemorrhoids Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hemorrhoids Global Clinical Trials Review, H2, 2017" provides an overview of Hemorrhoids clinical trials scenario. This report provides top line data relating to the clinical trials on Hemorrhoids. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical tri......
$2500